|By PR Newswire||
|September 3, 2014 09:34 AM EDT||
MARIETTA, Ga., Sept. 3, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, processor and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today the publication of another peer-reviewed scientific study in the scientific literature.
The Company's peer-reviewed article, "Cytokines in Single Layer Amnion/Chorion Allografts Compared to Multi-Layer Amnion/Chorion Allografts for Wound Healing," was electronically published in the Journal of Biomedical Materials Research Part B: Applied Biomaterials, on August 30, 2014. The paper was authored by Thomas J. Koob, PhD; Jeremy J. Lim, PhD; Nicole Zabek; and Michelle Massee. The electronic publication of the study in the Journal of Biomedical Materials Research is now available in the Wiley Online Library at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33265/pdf
The Company's previously published analyses have determined that over 50 growth factors, chemokines, cytokines, and regulatory factors are contained in PURION® Processed dehydrated human amnion/chorion membrane (dHACM) tissue allografts, specifically EpiFix®, a bilayer laminated graft containing both amnion and chorion. The scientific study was conducted to determine the relative contribution of each layer to the overall growth factor and cytokine content, as well as biological activity in the allograft. The study compared the results to the growth factor content in five representative commercially available single layer amnion grafts.
Study Highlights include:
- MiMedx's multilayer amnion/chorion grafts (EpiFix® and AmnioFix®) contain approximately 20 times more growth factors and cytokines than the competitive single layer amnion grafts evaluated in the study.
- AmbioDry2®, the MiMedx PURION® Processed single layer amnion, contains four to five times greater amounts of growth factors than the competitive single layer amnion products (DryFlex®, AmnioExCel®, SteriShield™, and SteriShield II™) that were evaluated in the study.
- EpiFix® contains four to five times the growth factors in AmbioDry2®.
- All single layer amnion grafts that were tested contained substantially fewer growth factors and cytokines, and therefore, will deliver significantly less growth factors and cytokines than MiMedx's amnion/chorion multilayer grafts with the same surface area.
- When calculated per surface area of tissue applied to a wound, the evaluated PURION® Processed amnion contained on average only 25% of the growth factor content contained in the PURION® Processed chorion.
- The chorion layer in the MiMedx multi-layered allografts is four to five times thicker than the amnion layer, and therefore, contributes disproportionately to the growth factor content in amnion/chorion grafts. Chorion contributes on average 82% of the growth factors in EpiFix®.
"Recently, there has been misinformation in the market making the generalization that all amniotic membrane grafts are similar, regardless of whether they are single layer amnion or multi-layer allografts," said Parker H. Petit, Chairman and CEO. "This study confirms that there is a substantial differentiation between multi-layer allografts with both amnion and chorion versus the single layer amnion allografts tested. This scientific study clearly demonstrates that PURION® Processed allografts with both amnion and chorion have a multiple of approximately 20 times more cytokines than the competitive single layer amnion allografts evaluated in the study."
To examine the role of tissue processing technique in cytokine retention, cytokine contents in representative dehydrated single layer wound care products (DryFlex®, AmnioExCel®, SteriShield™ Single Layer, and SteriShield II™ Dual Layer) were measured. The results demonstrated that cytokine content varied significantly among the allografts tested, and that PURION® Processed single layer amnion grafts, AmbioDry2®, contained significantly more cytokines than the other single layer products that were evaluated in the study. "AmbioDry2® is the single layer wound care product MiMedx processes for its ophthalmic partner, IOP Ophthalmics, Inc. These results suggest that, as compared to other methods of tissue processing, the proprietary PURION® Processing contributes to greater cytokine retention and the delivery of substantially more growth factors, which are known to be critically important in wound repair and tissue regeneration," commented Bill Taylor, President and COO.
The publication suggests that the retention of biologically active growth factors during processing of amniotic tissues is critically important in preserving the bioactivity of the native tissues for wound care. "The abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds," stated Taylor.
The ability to induce fibroblast proliferation was studied, and it was determined that both the amnion and chorion caused dermal fibroblasts to proliferate. However, the chorion per square cm was on average five times more effective at inducing proliferation. "The study determined that the predominant basis for the bioactivity is derived from the chorion. This is a clear indication that the biological activity in EpiFix® that induces fibroblast proliferation is a result of both our proprietary processing technique and the graft's multi-layer configuration with both amnion and chorion," concluded Petit.
DryFlex®and AmnioExCel® are registered trademarks, and SteriShield™ and SteriShield II™ are trademarks of their respective owners. AmbioDry2® is private labeled for, and is a registered trademark of, IOP Ophthalmics, Inc.
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
Safe Harbor Statement
This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to the importance of biologically active growth factors during processing of amniotic tissues in preserving the bioactivity of the native tissues for wound care and the contribution of the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts to these allografts' effectiveness in promoting the healing of refractive wounds. These statements are based on current information and belief, and are not guarantees of future performance. Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the retention of biologically active growth factors during processing of amniotic tissues may prove not to be as important in preserving the bioactivity of the native tissues for wound care as the study suggests, that, in a head-to-head study, the abundance of growth factors that results from combining amnion and chorion in the MiMedx dHACM allografts may be found not to contribute to these allografts being a more effective treatment in promoting the healing of refractive wounds, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2013. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.
SOURCE MiMedx Group, Inc.
Sep. 1, 2015 08:15 PM EDT Reads: 415
Sep. 1, 2015 07:00 PM EDT Reads: 269
Sep. 1, 2015 06:45 PM EDT Reads: 475
Sep. 1, 2015 04:30 PM EDT Reads: 387
Sep. 1, 2015 04:15 PM EDT Reads: 435
Sep. 1, 2015 04:00 PM EDT Reads: 196
Sep. 1, 2015 04:00 PM EDT Reads: 207
Sep. 1, 2015 03:00 PM EDT Reads: 509
Sep. 1, 2015 03:00 PM EDT Reads: 439
Sep. 1, 2015 02:45 PM EDT
Sep. 1, 2015 02:45 PM EDT Reads: 137
Sep. 1, 2015 02:30 PM EDT Reads: 214
Sep. 1, 2015 01:00 PM EDT
Sep. 1, 2015 12:45 PM EDT Reads: 479
Enterprises can achieve rigorous IT security as well as improved DevOps practices and Cloud economics by taking a new, cloud-native approach to application delivery. Because the attack surface for cloud applications is dramatically different than for highly controlled data centers, a disciplined and multi-layered approach that spans all of your processes, staff, vendors and technologies is required. This may sound expensive and time consuming to achieve as you plan how to move selected applicati...
Sep. 1, 2015 12:30 PM EDT